Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries
- Authors:
- Ivan Marques Borrello
- Madeline Mag Schaffer
- Elena Roehrl
- Jessica Falco Marshall
View Affiliations
Affiliations: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA, European Institute for Medical and Scientific Education, 1010 Vienna, Austria, Advanced Studies in Medicine, Somerville, NJ 08876, USA
- Published online on: January 14, 2014 https://doi.org/10.3892/mco.2014.242
-
Pages:
269-274
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The treatment of cancer has changed significantly over the past decade, from a treatment paradigm based primarily on surgery, chemotherapy and radiotherapy, to the development of targeted therapies involving tumor‑specific signaling pathways, as well as the immune system. Recent developments have demonstrated the significant clinical benefits of immunotherapy that are quickly being established as standard treatments for certain malignancies. In this study, we demonstrated that clinical practice is not keeping pace with advancing immuno‑oncology principles and research. We further demonstrated that the incorporation of immunotherapeutic approaches into the treatment of cancer patients varies widely, not only between developed and developing countries, but also between countries in specific geographical areas that have experienced similar cultural and economic development. We developed a survey to assess the deficiencies in scientific understanding, access to information and treatment options and investigated the differences in clinical practice behaviors among oncologists from six European countries: France, Germany, Greece, Italy, Spain and the United Kingdom. Our data demonstrated significant differences in all the categories assessed. Therefore, we concluded that there is a need to develop similar assessment tools to identify care imbalances, so that initiatives may be developed to correct care inequities that ultimately affect patient outcomes worldwide.
View References
|
1
|
DeVita VT Jr and Rosenberg SA: Two hundred
years of cancer research. N Engl J Med. 366:2207–2214.
2012.PubMed/NCBI
|
|
2
|
US Department of Health and Human
Services. First monoclonal antibody approved to treat cancer [press
release]. November 26–1997, http://archive.hhs.gov/news/press/1997pres/971126.html.
accessed June 17, 2013
|
|
3
|
Boyiadzis M and Foon KA: Approved
monoclonal antibodies for cancer therapy. Expert Opin Biol Ther.
8:1151–1158. 2008. View Article : Google Scholar
|
|
4
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn OJ: Immuno-oncology: understanding
the function and dysfunction of the immune system in cancer. Ann
Oncol. 23:viii6–viii9. 2012.PubMed/NCBI
|
|
6
|
Hoos A and Britten CM: The immuno-oncology
framework: enabling a new era of cancer therapy. Oncoimmunology.
1:334–339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borghaei H, Smith MR and Campbell KS:
Immunotherapy of cancer. Eur J Pharmacol. 625:41–54. 2009.
View Article : Google Scholar
|
|
8
|
Butterfield LH, Disis ML, Khleif SN,
Balwit JM and Marincola FM: Immuno-oncology biomarkers 2010 and
beyond: perspectives from the iSBTc/SITC biomarker task force. J
Transl Med. 8:1302010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
FDA approval letter to Dendreon
Corporation. April 29–2010, http://www.fda.gov/BiologicsBloodVaccines/CellulargeneTherapyProducts/ApprovedProducts/ucm210215.htm.
accessed June 17, 2013
|
|
10
|
US Department of Health and Human
Services, Food and Drug Administration. BLA approval letter, YERVOY
(ipilimumab). March 25–2011, http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125377s000ltr.pdf.
accessed June 17, 2013
|
|
11
|
Committee for Medicinal Products for Human
Use, European Medicines Agency. Assessment Report for Yervoy
(ipilimumab). Procedure number: EMEA/H/C/002213. May 19–2011,
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002213/WC500109302.pdf.
accessed June 17, 2013
|
|
12
|
Abdel-Wahab M, Alfonso R, Anacak Y, et al:
Human Health Reports No. 3: Inequity in cancer care: a global
perspective. International Atomic Energy Agency; Vienna, Austria:
pp. 1–51. 2011
|
|
13
|
Casali PG: Medical oncology: the
long-awaited prize of recognition. Ann Oncol. 8:1695–1697. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolchok JD, Hoos A, O’Day S, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumors: Revised
RECIST guideline (version 1.1). EJC. 45:228–247. 2009. View Article : Google Scholar
|
